NEWS | alsv

Companies in the News

Ring Therapeutics Raises $86.5M in Series C Funding to Create Next Generation Programmable Medicines

Ring raised a total of $86.5 million from new and returning investors, validating its unique approach to creating next-generation...

Aera Therapeutics Launches with $193 M for the Next Generation of Transformative Genetic Medicines

Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range...

Tessera Therapeutics Highlights Advancements Across its Gene Writing™ and Delivery Platforms

RNA Gene Writing™ platform demonstrates clinically relevant levels of in vivo rewriting in the genome of liver cells of non-human...

eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin

Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated...

DNA Writing Goes Enzymatic, Encourages Pursuit of Bold Visions

The 1950s are widely recognized as one of the most important decades in biology. This is, in large part, due to the discovery of the...

Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

Phase 1b study designed to determine the safety and dose of NUV-868 in combination with olaparib or enzalutamide for the treatment of...

Federation Bio Administers First Dose in Phase 1 Clinical Trial

- Study will assess the safety, efficacy and engraftment of FB-001 for the treatment of enteric hyperoxaluria, a serious metabolic...

Escient Pharmaceuticals Announces $120 Million Series C Financing

Financing led by New Enterprise Associates (NEA), Abingworth and Forge Life Science Partners Proceeds support advancement of EP262 and...

Indigo Expands 2023 Biological Crop Protection Line with New Biofungicide

MEMPHIS, Tenn., Nov. 22, 2022 /PRNewswire/ -- Indigo Agriculture today announced the commercial launch of the industry's first biological...